QLi5 Therapeutics GmbH

https://www.qli5tx.com

QLi5 was founded in 2019 as a joint venture of Qurient Co. Ltd, Korea, Max Planck Society (MPG), Germany, Lead Discovery Center (LDC), Germany, Nobel laureate Prof. Robert Huber, emeritus director of the Max Planck Institute for Biochemistry, Germany. The company has established a proprietary platform for the development of proteasome inhibitors with high selectivity and unique, non-covalent binding properties. Using the proceeds of a EUR 10 million series A financing in 2022, the company is advancing its pipeline and preparing clinical trials in various indications including cancer, inflammation and autoimmune diseases. The key role of the proteasome is the elimination of misfolded, damaged or expired proteins. The principle of proteasome inhibition was discovered in many years of basic research by the Max Planck Society. The extremely complex multi-subunit protein 3D-structure of the constitutive and immunoproteasome was resolved by Prof. Huber’s lab. This solid structural understanding enabled the development of novel chemical series of proteasome inhibitors with a wide range of selectivity. *

	Start	2020-01-16 established (s-off)
	Industry	proteasome inhibitor
	Industry 2	drug development

	Region	Dortmund
	Country	Germany
	Street	15 Otto-Hahn-Str.
	City	44227 Dortmund
		Address record changed: 2022-09-27

Basic data	Employees	n. a.

		* Document for »About Section«: QLi5 Therapeutics GmbH. (9/7/22). "Press Release: QLi5 Therapeutics Attracts EUR 10 Million in Series A Financing". Dortmund.

		Record changed: 2023-12-30